688373 Stock Overview
A biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Shanghai MicuRx Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥3.86 |
| 52 Week High | CN¥8.27 |
| 52 Week Low | CN¥3.23 |
| Beta | 0.64 |
| 11 Month Change | 1.58% |
| 3 Month Change | -7.88% |
| 1 Year Change | -44.70% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -41.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688373 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 2.4% | 2.4% | 5.4% |
| 1Y | -44.7% | -27.2% | -16.2% |
Return vs Industry: 688373 underperformed the CN Biotechs industry which returned -27.2% over the past year.
Return vs Market: 688373 underperformed the CN Market which returned -16.2% over the past year.
Price Volatility
| 688373 volatility | |
|---|---|
| 688373 Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in CN Market | 8.4% |
| 10% least volatile stocks in CN Market | 3.7% |
Stable Share Price: 688373 has not had significant price volatility in the past 3 months.
Volatility Over Time: 688373's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 188 | Yuan Zhengyu | www.micurxchina.com |
Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs. It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria; MRX-5 for multidrug-resistant gram-negative bacteria; MRX-7 for multidrug-resistant gram-positive bacteria; MRX-15 and MRX-17 to treat kidney disease; MRX-18 for the treatment of COVID-19; and MRX-23 for the treatment of tumour. Shanghai MicuRx Pharmaceutical Co., Ltd.
Shanghai MicuRx Pharmaceutical Co., Ltd. Fundamentals Summary
| 688373 fundamental statistics | |
|---|---|
| Market cap | CN¥2.53b |
| Earnings (TTM) | -CN¥497.31m |
| Revenue (TTM) | CN¥109.40m |
23.4x
P/S Ratio-5.1x
P/E RatioIs 688373 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688373 income statement (TTM) | |
|---|---|
| Revenue | CN¥109.40m |
| Cost of Revenue | CN¥20.06m |
| Gross Profit | CN¥89.34m |
| Other Expenses | CN¥586.65m |
| Earnings | -CN¥497.31m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.76 |
| Gross Margin | 81.66% |
| Net Profit Margin | -454.56% |
| Debt/Equity Ratio | 27.8% |
How did 688373 perform over the long term?
See historical performance and comparison